title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - Climb Bio  ( NASDAQ:CLYM ) ",20241111T120000,https://www.benzinga.com/pressreleases/24/11/g41875065/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board,BIIB,0.111488,Neutral,-0.048758
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board",20241111T120000,https://www.globenewswire.com/news-release/2024/11/11/2978194/0/en/Climb-Bio-Appoints-Douglas-E-Williams-Ph-D-as-Chair-of-the-Board.html,BIIB,0.066877,Neutral,-0.045153
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal,20240904T153200,https://www.zacks.com/stock/news/2331539/atha-stock-tanks-as-alzheimers-study-fails-to-meet-primary-goal,BIIB,0.328455,Bullish,0.369796
Eli Lilly  ( LLY )  Gets FDA Nod for Alzheimer's Drug Donanemab,20240703T123400,https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimers-drug-donanemab,BIIB,0.219809,Somewhat-Bullish,0.251132
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?,20240619T170000,https://www.zacks.com/stock/news/2290613/can-eli-lilly-etfs-surge-on-approval-of-alzheimers-drug,BIIB,0.250386,Neutral,0.060737
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab  ( Revised ) ,20240614T152100,https://www.zacks.com/stock/news/2288637/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab-revised,BIIB,0.421485,Somewhat-Bullish,0.298879
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune  ( Revised ) ",20240614T151000,https://www.zacks.com/stock/news/2288638/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune-revised,BIIB,0.422897,Somewhat-Bullish,0.251811
"The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune",20240613T100900,https://www.zacks.com/stock/news/2287623/the-zacks-analyst-blog-highlights-biogen-eli-lillys-prothena-and-ac-immune,BIIB,0.431554,Somewhat-Bullish,0.255128
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab,20240612T142200,https://www.zacks.com/stock/news/2287324/alzheimers-in-focus-as-fda-panel-endorses-lillys-donanemab,BIIB,0.431065,Somewhat-Bullish,0.303139
"The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity",20231212T141000,https://www.zacks.com/stock/news/2196695/the-zacks-analyst-blog-highlights-biogen-prothena-ac-immunes-and-vaxxinity,BIIB,0.170878,Neutral,0.131235
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus,20231211T140600,https://www.zacks.com/stock/news/2196083/alzheimers-disease-space-evolves-in-2023-stocks-in-focus,BIIB,0.136888,Somewhat-Bullish,0.191134
"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ",20231121T201625,https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o,BIIB,0.229149,Neutral,-0.07556
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,BIIB,0.069495,Neutral,0.0
Biogen  ( BIIB )  & Eisai's Lecanemab Secures EMA's MAA Acceptance,20230127T145700,https://www.zacks.com/stock/news/2045510/biogen-biib-eisais-lecanemab-secures-emas-maa-acceptance,BIIB,0.352223,Somewhat-Bullish,0.292167
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",20230118T120047,https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,BIIB,0.063425,Neutral,-0.038049
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,BIIB,0.112269,Neutral,-0.094787
"Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen",20220617T123100,https://www.zacks.com/stock/news/1940270/roche-alzheimers-candidate-failure-hurts-lilly-biogen,BIIB,0.31482,Neutral,-0.064442
Roche's experimental Alzheimer's drug crenezumab fails to prevent cognitive decline in people | The Financial Express,20220617T084432,https://www.financialexpress.com/healthcare/pharma-healthcare/roches-experimental-alzheimers-drug-crenezumab-fails-to-prevent-cognitive-decline-in-people/2564179/,BIIB,0.106164,Bearish,-0.436942
"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",20220616T140943,https://www.benzinga.com/general/biotech/22/06/27737919/the-daily-biotech-pulse-roches-alzheimers-drug-fails-advisors-back-pfizer-moderna-shots-for-young,BIIB,0.147607,Neutral,0.000232
"Alzheimer's Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220505T112802,https://www.benzinga.com/pressreleases/22/05/g27015849/alzheimers-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,BIIB,0.031454,Neutral,0.021912
"Alzheimer Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis",20220317T094130,https://www.benzinga.com/pressreleases/22/03/g26178322/alzheimer-drugs-market-size-2022-2028-industry-size-share-growth-trends-forecast-analysis,BIIB,0.072032,Neutral,-0.132033
BioCryst Pharmaceuticals  ( NASDAQ:BCRX )  - BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200110,https://www.benzinga.com/pressreleases/22/09/g28872104/biocryst-names-dr-bill-sheridan-chief-development-officer-and-appoints-dr-ryan-arnold-chief-medica,BIIB,0.06623,Neutral,0.044129
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200100,https://www.globenewswire.com/news-release/2022/09/14/2516384/29446/en/BioCryst-Names-Dr-Bill-Sheridan-Chief-Development-Officer-and-Appoints-Dr-Ryan-Arnold-Chief-Medical-Officer.html,BIIB,0.069697,Neutral,0.045268
Co. Advancing Drug Class With Broad Potential,20220914T160429,https://www.investorideas.com/news/2022/biotech/09142Advancing-Drug-Class.asp,BIIB,0.041901,Neutral,0.0
ANNX: Insider Buying Sends Annexon Stock Higher. But Does That Make It a Buy?,20220721T131546,https://stocknews.com/news/annx-vrtx-amgn-biib-insider-buying-sends-annexon-stock-higher-but-does-that-make/,BIIB,0.137671,Neutral,0.041143
"Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology",20240912T133000,https://www.benzinga.com/pressreleases/24/09/g40833623/gene-therapy-market-set-for-19-cagr-surge-reaching-usd-38-34-billion-by-2031-skyquest-technology,BIIB,0.039878,Neutral,0.026899
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive ... - PR Newswire,20231201T183000,https://www.prnewswire.com/news-releases/neuromuscular-disease-therapeutics-market-size-to-grow-by-usd-65-13-billion-from-2022-2027-aquestive-therapeutics-inc-bausch-health-companies-inc-biogen-inc-and-more-among-the-major-companies-in-the-market--technavio-302002042.html,BIIB,0.059636,Neutral,0.014995
"Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket - AIM ImmunoTech  ( AMEX:AIM ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",20220928T111722,https://www.benzinga.com/news/22/09/29048520/why-mindmed-is-trading-lower-by-around-35-here-are-31-stocks-moving-premarket,BIIB,0.299478,Bullish,0.371268
"Earnings Scheduled For May 3, 2022",20220503T085235,https://www.benzinga.com/news/earnings/22/05/26953640/earnings-scheduled-for-may-3-2022,BIIB,0.01558,Neutral,0.000324
Biogen Inc.  ( BIIB )  Q3 Earnings and Revenues Surpass Estimates,20241030T120506,https://www.zacks.com/stock/news/2360294/biogen-inc-biib-q3-earnings-and-revenues-surpass-estimates,BIIB,0.405651,Neutral,0.144264
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,BIIB,0.078099,Neutral,0.0
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,BIIB,0.040795,Neutral,0.143852
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",20230130T105418,https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,BIIB,0.035983,Neutral,0.104395
Why Gilead's Cancer Biz Is Driving The Stock To A Fever Pitch,20221123T124500,https://www.investors.com/news/technology/gild-stock-surges-why-gilead-sees-its-oncology-business-as-a-force-to-be-reckoned-with/,BIIB,0.032338,Somewhat-Bullish,0.29218
"An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week - Stitch Fix  ( NASDAQ:SFIX ) , Biogen  ( NASDAQ:BIIB ) ",20231024T164130,https://www.benzinga.com/markets/penny-stocks/23/10/35399377/an-oversold-small-cap-industrial-that-insiders-are-buying-ahead-of-earnings-this-week,BIIB,0.196344,Neutral,0.109088
"DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday - Axsome Therapeutics  ( NASDAQ:AXSM ) , Biogen  ( NASDAQ:BIIB ) ",20230808T114336,https://www.benzinga.com/news/earnings/23/08/33624476/draftkings-to-rally-over-38-here-are-10-other-analyst-forecasts-for-tuesday,BIIB,0.28442,Neutral,0.006401
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ,20230613T110000,https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di,BIIB,0.009551,Neutral,0.062837
